Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review

References

• Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13 ed. Washington, D.C.: Public Health Foundation; 2015.
   Google Scholar
• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MAP. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36. doi:10.1016/j.vaccine.2011.12.032.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Blain AE, Wang X, Cohn AC. Current Epidemiology and Trends in Meningococcal Disease—United States, 1996–2015. Clin Infec Dis. 2018;66(8):1276–81. doi:10.1093/cid/cix993.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Schutze GE, Leake JA, Barson WJ, Halasa NB, Byington CL, Tan TQ, Hoffman JA, Wald ER, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. 2006;118(4):e979–984. doi:10.1542/peds.2006-0281.
   PubMed Web of Science ®Google Scholar
• Madelaine T, Cour M, Bohé J, Floccard, Duperret S, Hernu R, Argaud L. Invasive meningococcal disease-induced myocarditis in critically ill adult patients: initial presentation and long-term outcome. Intensive Care Med. 2017;43(2):279–81. doi:10.1007/s00134-016-4623-x.
   PubMed Web of Science ®Google Scholar
• Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. 1996;15(11):967–79. quiz 979. doi:10.1097/00006454-199611000-00009.
   PubMed Web of Science ®Google Scholar
• Edwards MS, Baker CJ. Complications and sequelae of meningococcalinfections in children. J Pediatr. 1981;99(4):540–45. doi:10.1016/S0022-3476(81)80250-8.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner CH, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend Rep. 2013;62(RR–2):1–28.
   PubMed Web of Science ®Google Scholar
• Sanofi Pasteur Inc. Menactra package insert: highlights of prescribing information; 2018. [accessed date 2020 Jun 25]. https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert—Menactra.pdf
   Google Scholar
• GlaxoSmithKline Biologicals SA. MENVEO package insert: highlights of prescribing information; 2017. [accessed date 2020 Jun 25]. https://www.fda.gov/media/78514/download
   Google Scholar
• Sanofi Pasteur Inc. MenQuadfi, Meningococcal (Groups A, C, Y, W) conjugate vaccine; 2020. [accessed date 2020 Jun 29]. https://www.fda.gov/media/137306/download.
   Google Scholar
• MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep. 2014;63:527–30.
   PubMed Web of Science ®Google Scholar
• Keshavan P, Pellegrini M, Vadivelu-Pechai K, Nissen M. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Rev Vaccines. 2018;17(10):865–80. doi:10.1080/14760584.2018.1521280.
   PubMed Web of Science ®Google Scholar
• Myers TR, McNeil MM. Current safety issues with quadrivalent meningococcal conjugate vaccines. Hum Vaccin Immunother. 2018;14(5):1175–78. doi:10.1080/21645515.2017.1366393.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Framework for FDA’s real-world evidence program; 2018. [accessed date 2020 Jun 04]. https://www.fda.gov/media/120060/download.
   Google Scholar
• Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the vaccine adverse event reporting system. Am J Obstet Gynecol. 2013;208(6):478.e471-476. doi:10.1016/j.ajog.2013.02.027.
   PubMed Web of Science ®Google Scholar
• Becerra-Culqui TA, Sy LS, Ackerson BK, Chen LH, Fischetti CA, Solano Z, Schmidt JE, Malvisi L, Curina C, Pellegrini M, et al. Safety of MenACWY-CRM vaccine exposure during pregnancy. Vaccine. 2020;38(12):2683–90. doi:10.1016/j.vaccine.2020.02.008.
   PubMed Web of Science ®Google Scholar
• Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015. Vaccine. 2017;35(14):1758–63. doi:10.1016/j.vaccine.2017.02.030.
   PubMed Web of Science ®Google Scholar
• Hansen J, Zhang L, Klein NP, Robertson CA, luo MD, Greenberg DP, Bassily E, Baxter R. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017;35(49):6879–84. doi:10.1016/j.vaccine.2017.09.032.
   PubMed Web of Science ®Google Scholar
• Becerra-Culqui TA, Sy LS, Ackerson BK, Slezak JM, Luo Y, Fischetti CA, Ohadike YU, Curina C, Pellegrini M, Solano Z, et al. Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old. Vaccine. 2020;38(2):228–34.
   Google Scholar
• Hansen J, Zhang L, Eaton A, Baxter R, Robertson CA, Decker MD, Greenberg DP, Bassily E, Klein NP. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children. Vaccine. 2018;36(16):2133–38. doi:10.1016/j.vaccine.2018.02.107.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Sy LS, Ackerson BK, Hechter RC, Haag M, Slezak JM, Fischetti CA, Takhar HS, et al. Safety of Quadrivalent Meningococcal Conjugate Vaccine in Children 2–10 Years. Pediatr Infect Dis J. 2017;36(11):1087–92. doi:10.1097/INF.0000000000001696.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Update: guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine–United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006;55(41):1120–24.
   PubMedGoogle Scholar
• Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(12):1359–60. doi:10.1002/pds.3353.
   PubMed Web of Science ®Google Scholar
• Velentgas P, Amato AA, Bohn RL, Arnold Chan K, Cochrane T, Funch, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21(12):1350–58. doi:10.1002/pds.3321.
   PubMed Web of Science ®Google Scholar
• Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP. Recurrent Guillain-Barre syndrome following vaccination. Clin Infec Dis. 2012;54(6):800–04. doi:10.1093/cid/cir960.
   PubMed Web of Science ®Google Scholar
• Tseng H-F, Sy LS, Ackerson BK, Hechter RC, Tartof SY, Haag M, Slezak JM, Luo Y, Fischetti CA, Takhar HS, et al. Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-Year-Olds. Pediatrics. 2017;139(1):e20162084. doi:10.1542/peds.2016-2084.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Syncope after vaccination–United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457–60.
   PubMedGoogle Scholar
• Narwaney KJ, Breslin K, Ross CA, Shoup JA, Wain KF, Weintraub ES, McNeil MM, Hambidge SJ. Vaccine adverse events in a safety net healthcare system and a managed care organization. Vaccine. 2017;35(9):1335–40. doi:10.1016/j.vaccine.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Klein NP, Lewis N, Fireman B, Ray P, Rasgon B, Black S, Klein JO, Baxter R. Immunization and Bell’s Palsy in children: a case-centered analysis. Am J Epidemiol. 2012;175(9):878–85. doi:10.1093/aje/kws011.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Yu O, Nelson J, Belongia EA, Hambidge SJ, Baxter R, Naleway A, Nordin J, Baggs J, Iskander J, et al. Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. Vaccine. 2009;27(36):4912–16. doi:10.1016/j.vaccine.2009.06.038.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol. 2010;3(3):285–99. doi:10.1586/ehm.10.21.
   PubMed Web of Science ®Google Scholar
• Li R, Weintraub E, McNeil MM, Kulldorff M, Lewis EM, Nelson, Xu S, Qian L, Klein NP, Destefano F, et al. Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method. Pharmacoepidemiol Drug Saf. 2018;27(4):391–97. doi:10.1002/pds.4397.
   PubMed Web of Science ®Google Scholar
• Cheng MP, Pandit A, Antin JH, Walsh SR, Huynh D, Ghobrial IM, Baden LR, Marty FM, Issa NC. Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Advances. 2018;2(11):1272–76. doi:10.1182/bloodadvances.2018018911.
   PubMed Web of Science ®Google Scholar